Impact of Immuno-Oncologic Agent on Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
NCT ID: NCT05910710
Last Updated: 2023-06-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
50 participants
OBSERVATIONAL
2023-03-02
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
(Neoadjuvant Weekly paclitaxel, Carboplatin +- Pembrolizumab followed by Doxorubicin, Cyclophosphamide +- Pembrolizumab regimen)
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
LAG3 Expression in Triple Negative Breast Cancer
NCT06259162
Microbiome Immunotherapy Neoadjuvant Assessment
NCT06709651
Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab
NCT05877859
Study to Identify Molecular Mechanisms of Clinical Resistance to Chemotherapy in Triple Negative Breast Cancer Patients
NCT01276899
TME Alteration in HER2 Positive Breast Cancer
NCT06533670
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Subjects administered Neoadjuvant Pembrolizumab
Neoadjuvant Weekly paclitaxel, Carboplatin followed by Doxorubicin, Cyclophosphamide add Pembrolizumab
Visium, Whole Genome Sequencing(WGS)/Whole Transcriptome Sequencing(WTS)
Visium : Spatial transcriptomics WGS/WTS : detection of somatic mutation
Subjects not administered Neoadjuvant Pembrolizumab
Neoadjuvant Weekly paclitaxel, Carboplatin followed by Doxorubicin, Cyclophosphamide
Visium, Whole Genome Sequencing(WGS)/Whole Transcriptome Sequencing(WTS)
Visium : Spatial transcriptomics WGS/WTS : detection of somatic mutation
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Visium, Whole Genome Sequencing(WGS)/Whole Transcriptome Sequencing(WTS)
Visium : Spatial transcriptomics WGS/WTS : detection of somatic mutation
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects administered neoadjuvant Weekly paclitaxel, Carboplatin followed by Doxorubicin, Cyclophosphamide add Pembrolizumab or not
* Non pCR patients who are undergoing surgery after neoadjuvant chemotherapy
* Sign to informed consent
Exclusion Criteria
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Samsung Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yeon Hee Park
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Samsung Medical Center
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-02-019
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.